LP-284 demonstrates potency against treatment-resistant MCL cell lines
Oct. 3, 2022
Researchers from Lantern Pharma Inc. presented preclinical data for the small-molecule DNA-damaging agent LP-284, being developed for the treatment of hematological cancers.
